Actuate Therapeutics, Inc. Interest Expense Nonoperating
Actuate Therapeutics, Inc. (ACTU) reported Interest Expense Nonoperating of $5.06 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement
us-gaap:InterestExpenseNonoperating · last filed 2026-08-14
- Actuate Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-06-30 was $5.06K, a 0.02% increase year-over-year.
- Actuate Therapeutics, Inc. interest expense nonoperating for the quarter ending 2026-03-31 was $5.06K, a 0.02% decline year-over-year.
- Actuate Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-12-31 was $5.06K, a 0.28% decline year-over-year.
- Actuate Therapeutics, Inc. interest expense nonoperating for the quarter ending 2025-09-30 was $5.06K, a 45.11% increase year-over-year.
- Actuate Therapeutics, Inc. interest expense nonoperating for fiscal 2025 was $20.25K, a 8.19% increase from fiscal 2024.
- Actuate Therapeutics, Inc. interest expense nonoperating for fiscal 2024 was $18.72K, a 57.11% decline from fiscal 2023.
- Actuate Therapeutics, Inc. interest expense nonoperating for fiscal 2023 was $43.64K.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.06K 10-Q · filed 2026-08-14 | $10.13K 10-Q · filed 2026-08-14 | $15.19K derived: sum of 3 quarters · filed 2026-08-14 | $20.25K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | $5.06K 10-Q · filed 2026-05-14 | $10.12K derived: sum of 2 quarters · filed 2026-05-14 | $15.19K derived: sum of 3 quarters · filed 2026-05-14 | $20.25K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $5.06K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $10.13K derived: sum of 2 quarters · filed 2026-03-26 | $15.19K derived: sum of 3 quarters · filed 2026-08-14 | $20.25K 10-K · filed 2026-03-26 |
| 2025-09-30 | $5.06K 10-Q · filed 2025-11-13 | $10.13K derived: sum of 2 quarters · filed 2026-08-14 | $15.19K 10-Q · filed 2025-11-13 | $20.26K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $5.06K 10-Q · filed 2026-08-14 | $10.13K 10-Q · filed 2026-08-14 | $15.20K derived: sum of 3 quarters · filed 2026-08-14 | $18.69K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $5.06K 10-Q · filed 2026-05-14 | $10.14K derived: sum of 2 quarters · filed 2026-05-14 | $13.63K derived: sum of 3 quarters · filed 2026-05-14 | $18.70K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $5.08K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $8.56K derived: sum of 2 quarters · filed 2026-03-26 | $13.64K derived: sum of 3 quarters · filed 2026-03-26 | $18.72K 10-K · filed 2026-03-26 |
| 2024-09-30 | $3.49K 10-Q · filed 2025-11-13 | $8.56K derived: sum of 2 quarters · filed 2025-11-13 | $13.64K 10-Q · filed 2025-11-13 | $18.70K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $5.08K 10-Q · filed 2025-08-14 | $10.15K 10-Q · filed 2025-08-14 | $15.21K derived: sum of 3 quarters · filed 2025-08-14 | $20.28K derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $5.08K 10-Q · filed 2025-05-15 | $10.14K derived: sum of 2 quarters · filed 2025-05-15 | $15.20K derived: sum of 3 quarters · filed 2025-05-15 | $20.26K derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $5.06K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-13 | $10.13K derived: sum of 2 quarters · filed 2025-03-13 | $15.19K derived: sum of 3 quarters · filed 2025-03-13 | $43.64K 10-K · filed 2025-03-13 |
| 2023-09-30 | $5.06K 10-Q · filed 2024-11-13 | $10.12K derived: sum of 2 quarters · filed 2024-11-13 | $38.58K 10-Q · filed 2024-11-13 | |
| 2023-06-30 | $5.06K 10-Q · filed 2024-09-24 | $33.52K 10-Q · filed 2024-09-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| Tvardi Therapeutics, Inc. (TVRD) | United States | $0.014B | |
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| Korsana Biosciences, Inc. (CYCN) | United States | $0.016B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B |